PLATELET-DERIVED GROWTH FACTOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OSTEOCHONDRAL DEFECTS
The present invention provides compositions and methods for treating an osteochondral defect. In one embodiment, provided is a composition for treating an osteochondral defect comprising a biphasic biocompatible matrix and platelet derived growth factor (PDGF), wherein the biphasic biocompatible matrix comprises a scaffolding material and wherein the scaffolding material forms a porous structure comprising an osseous phase and a cartilage phase. In another embodiment, also provided is a method for treating an osteochondral defect in an individual comprising administering to the individual an effective amount of a composition comprising a biphasic biocompatible matrix and PDGF to at least one site of the osteochondral defect, wherein the biphasic biocompatible matrix comprises a scaffolding material and wherein the scaffolding material forms a porous structure comprising an osseous phase and a cartilage phase.
1 - 27 . (canceled)
28 . A composition for treating an osteochondral defect comprising a biphasic biocompatible matrix and platelet derived growth factor (PDGF) in a solution,
wherein the biphasic biocompatible matrix comprises a dual-layer scaffolding material comprising:
a) a top layer, wherein the top layer comprises a cartilage phase
b) a bottom layer, wherein the bottom layer comprises an osseous phase,
and wherein the scaffolding material forms a porous structure.
29 . The composition of claim 28 , wherein the osseous phase comprises a calcium phosphate.
30 . The composition of claim 28 , wherein the osseous phase comprises a calcium phosphate and collagen.
31 . The composition of claim 28 , wherein the osseous phase comprises a calcium phosphate and an allograft material.
32 . The composition of claim 28 , wherein the osseous phase comprises a calcium phosphate, collagen and an allograft material.
33 . The composition of claim 28 , wherein the osseous phase comprises a collagen and an allograft material.
34 . The composition of claim 28 , wherein the cartilage phase comprises collagen.
35 . The composition of claim 28 , wherein the cartilage phase comprises glycosaminoglycan.
36 . The composition of claim 28 , wherein the cartilage phase comprises glycosaminoglycan and collagen.
37 . The composition of claim 28 , wherein the cartilage phase comprises glycosaminoglycan, an allograft material and collagen.
38 . The composition of claim 28 , wherein the biocompatible matrix further comprises a biocompatible binder.
39 . A method for treating an osteochondral defect in an individual comprising administering to the individual an effective amount of a composition comprising a biphasic biocompatible matrix and platelet derived growth factor (PDGF) in a solution,
wherein the biphasic biocompatible matrix comprises a dual-layer scaffolding material comprising:
a) a top layer, wherein the top layer comprises a cartilage phase
b) a bottom layer, wherein the bottom layer comprises an osseous phase,
and wherein the scaffolding material forms a porous structure.
40 . The method of claim 39 , wherein the osteochondral defect is in a cartilage and a bone adjacent to the cartilage, and wherein the cartilage comprises articular cartilage.
41 . The method of claim 39 , wherein the osteochondral defect is in a cartilage and a bone adjacent to the cartilage, and wherein the bone adjacent to the cartilage comprises a subchondral bone or a cancellous bone.
42 . The method of claim 39 , wherein the at least one site of the osteochondral defect comprises the bone adjacent to the cartilage, the cartilage, an interface between the cartilage and the bone adjacent to the cartilage, or combinations thereof.
43 . The method of claim 39 , wherein the osseous phase comprises a calcium phosphate and collagen.
44 . The method of claim 39 , wherein the osseous phase comprises an allograft material and collagen.
45 . The method of claim 39 , wherein the cartilage phase comprises a glycosaminoglycan and collagen.
46 . The method of claim 39 , wherein the cartilage phase comprises a glycosaminoglycan and an allograft material.
47 . The method of claim 39 , wherein the biphasic biocompatible matrix further comprises a biocompatible binder.